Related Experiment Videos
Identification of mar mutations in herpes simplex virus type 1 glycoprotein B which alter antigenic structure and
S L Highlander1, D J Dorney, P J Gage
1Program in Cellular and Molecular Biology, University of Michigan Medical School, Ann Arbor 48109.
Abstract:
Analysis of six monoclonal antibody-resistant (mar) mutants in herpes simplex virus type 1 glycoprotein B identified two type-common (II and III) and two type-specific (I and IV) antigenic sites on this molecule. To derive additional information on the location of these sites, mar mutations were mapped and nucleotide alterations were identified by DNA sequencing. Each mutant carried a single amino acid substitution resulting from a G-to-A base transition. Alterations affecting antibody neutralization were identified at residues 473, 594, 305, and 85 for mutants in sites I through IV, respectively. Two clonally distinct site II antibodies each selected mar mutants (Gly to Arg at residue 594) that exhibited a reduction in the rate of entry (roe) into host cells. A site II mar revertant that regained sensitivity to neutralization by site II antibodies also showed normal entry kinetics. DNA sequencing of this virus identified a single base reversion of the site II mar mutation, resulting in restoration of the wild-type sequence (Arg to Gly). This finding demonstrated that the mar and roe phenotypes were the result of a single mutation. To further define structures that contributed to antibody recognition, monoclonal antibodies specific for all four sites were tested for their ability to immune precipitate a panel of linker-insertion mutant glycoprotein B molecules. Individual polypeptides that contained single insertions of 2 to 28 amino acids throughout the external domain were not recognized or were recognized poorly by antibodies specific for sites II and III, whereas no insertion affected antibody recognition of sites I and IV. mar mutations affecting either site II or III were previously shown to cause temperature-sensitive defects in glycoprotein B glycosylation, and variants altered in both these sites were temperature sensitive for virus production. Taken together, the data indicate that antigenic sites II and III are composed of higher-order structures whose integrity is linked with the ability of glycoprotein B to function in virus infectivity.
Insights
Herpes simplex virus type 1 glycoprotein B has four antigenic sites. Mutations affecting antibody neutralization sites II and III impact viral entry and function, suggesting these sites involve complex structures essential for infectivity.
Area of Science:
- Virology
- Immunology
- Structural Biology
Background:
- Herpes simplex virus type 1 (HSV-1) glycoprotein B (gB) is crucial for viral entry and is a target for neutralizing antibodies.
- Monoclonal antibody-resistant (mar) mutants have been instrumental in mapping antigenic sites on viral proteins.
Purpose of the Study:
- To map the antigenic sites on HSV-1 glycoprotein B and understand their structural basis.
- To investigate the relationship between antibody recognition sites and gB function in viral entry and infectivity.
Main Methods:
- Analysis of monoclonal antibody-resistant (mar) mutants to identify antigenic sites on HSV-1 gB.
- DNA sequencing to identify nucleotide alterations and corresponding amino acid substitutions in mar mutants.
- Immune precipitation assays using linker-insertion mutants to probe antibody recognition of gB structures.
Main Results:
- Four antigenic sites (I-IV) were identified on HSV-1 gB, with sites II and III being type-common.
- Mutations in antigenic sites II and III affected antibody neutralization, viral entry rates, and caused temperature-sensitive defects in gB glycosylation.
- Linker-insertion mutations disrupted recognition of sites II and III by specific antibodies, indicating these sites depend on higher-order structures.
Conclusions:
- Antigenic sites II and III on HSV-1 gB are composed of higher-order structures.
- The integrity of these higher-order structures is essential for gB function in virus infectivity, including entry and glycosylation.